VIVOS INC Files Q2 2024 10-Q

TL;DR

VIVOS INC dropped its Q2 10-Q, check financials for the medical instrument maker.

AI Summary

VIVOS INC filed its 10-Q for the period ending June 30, 2024. The company, formerly known as ADVANCED MEDICAL ISOTOPE Corp, is based in Richland, WA, and operates in the surgical and medical instruments sector. The filing covers financial information for the second quarter of 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational details for VIVOS INC, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant risks or opportunities, but without specific financial performance data in the provided text, a definitive risk level is hard to assign.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
• 20240813 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• VIVOS INC (company) — Filer
• ADVANCED MEDICAL ISOTOPE Corp (company) — Former company name
• 719 JADWIN AVENUE (location) — Business and Mail Address
• RICHLAND (location) — City
• WA (location) — State
• 99352 (location) — ZIP Code
• 509-736-4000 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $9 million — any believes it will cost approximately $9 million to: (1) fund the FDA approval process t

Filing Documents

• form10-q.htm (10-Q) — 970KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001493152-24-031540.txt ( ) — 4743KB
• rdgl-20240630.xsd (EX-101.SCH) — 27KB
• rdgl-20240630_cal.xml (EX-101.CAL) — 28KB
• rdgl-20240630_def.xml (EX-101.DEF) — 152KB
• rdgl-20240630_lab.xml (EX-101.LAB) — 272KB
• rdgl-20240630_pre.xml (EX-101.PRE) — 212KB
• form10-q_htm.xml (XML) — 885KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1. Financial Condensed Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Condensed Statements of Operations for the Six and Three Months ended June 30, 2024 and 2023 (unaudited) 2 Condensed Statement of Changes in Stockholders' Equity for the Six Months ended June 30, 2024 and 2023 (unaudited) 3 Condensed Statements of Cash Flow for the Six Months ended June 30, 2024 and 2023 (unaudited) 4 Notes to Condensed Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 i PART I – FINANCIAL INFORMATION VIVOS INC BALANCE SHEETS JUNE 30, 2024 (UNAUDITED) AND DECEMBER 31, 2023 JUNE 30, DECEMBER 31, 2024 2023 (UNAUDITED) ASSETS Current Assets: Cash $ 1,724,417 $ 1,592,287 Accounts receivable 13,500 7,000 Prepaid expenses 31,748 10,837 Total Current Assets 1,769,665 1,610,124 TOTAL ASSETS $ 1,769,665 $ 1,610,124 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Current Liabilities: Accounts payable and accrued expenses $ 166,560 $ 245,004 Total Current Liabilities 166,560 245,004 Total Liabilities 166,560 245,004 Commitments and contingencies - - STOCKHOLDERS' EQUITY Preferred stock, par value, $ 0.001 , 20,000,000 shares authorized, Series A Convertible Preferred, 5,000,000 shares authorized, 2,071,007 shares issued and outstanding, respectively 2,071 2,071 Additional paid in capital - Series A Convertible preferred stock 8,842,458 8,842,458 Series B Convertible Preferred, 5,000,000 shares authorized, 200,363 shares issued and outstanding, respectively 200 200 Additional paid in capital - Series B Convertible preferred stock 290,956 290,956 Series C Convertible Preferred, 5,000,000 shares authorized, 385,302 shares issued and outstanding, respectively 385 385 Preferred stock value 385 385 Additional paid in capital - Series C Convertible preferred stock 500,507 500,507 Additional paid in capital 500,507 500,507 Common stock, par value, $ 0.001 , 950,000,000 shares authorized, 417,681,245 and 387,894,033 issued and outstanding, respectively 417,681 387,894 Additional paid in capital - common stock 75,061,625 73,791,430 Accumulated deficit ( 83,512,778 ) ( 82,450,781 ) Total Stockholders' Equity 1,603,105 1,365,120 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,769,665 $ 1,610,124 The accompanying notes are an integral part of these unaudited condensed financial statements. 1 VIVOS INC OF

Business

Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (" SMSC "). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock, $ 0.001 par value per share, and 20,000,000 shares of preferred stock, $ 0.001 par value per share. Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol "RDGL." The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel , for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company's development efforts. The Company's overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (" FDA ") Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no add

View Full Filing

View this 10-Q filing on SEC EDGAR